Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 11.2% – Here’s Why

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price traded up 11.2% during trading on Monday . The company traded as high as $16.58 and last traded at $16.52. 551,300 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 1,989,365 shares. The stock had previously closed at $14.86.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. TD Cowen reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Sanford C. Bernstein set a $23.00 price target on shares of Dyne Therapeutics in a report on Tuesday, December 9th. HC Wainwright dropped their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Chardan Capital reissued a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a report on Monday. Finally, Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.13.

Dyne Therapeutics Stock Up 11.8%

The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25. The stock has a market capitalization of $3.26 billion, a PE ratio of -5.59 and a beta of 1.34. The company has a 50 day moving average price of $17.02 and a 200-day moving average price of $17.20.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Brian S. Posner purchased 3,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average cost of $15.06 per share, with a total value of $45,180.00. Following the completion of the purchase, the director directly owned 11,500 shares in the company, valued at approximately $173,190. This represents a 35.29% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.77% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Chung Wu Investment Group LLC purchased a new stake in Dyne Therapeutics in the third quarter worth $30,000. Strs Ohio bought a new stake in shares of Dyne Therapeutics during the 4th quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Dyne Therapeutics by 25.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after buying an additional 1,109 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Dyne Therapeutics in the 4th quarter worth about $84,000. Finally, Ameritas Investment Partners Inc. grew its position in shares of Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock worth $91,000 after buying an additional 955 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.